Zacks Investment Research upgraded shares of YM BIOSCI INC (YMI) from NEUTRAL to OUTPERFORM on July 23, 2012, with a target price of $2.30.
YM BioSciences Inc. is a cancer drug development company.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on YM BIOSCI INC (YMI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment